Assistive Soft Robotic Glove (EsoGLOVE) Intervention for Stroke Patients

Last updated: May 29, 2026
Sponsor: Alexandra Hospital
Overall Status: Completed

Phase

N/A

Condition

Stroke

Cerebral Ischemia

Treatment

EsoGLOVE with Trigno Biofeedback (EMG sensors)

Graded Repetitive Arm Supplementary Program (GRASP)

EsoGLOVE

Clinical Study ID

NCT05995665
2020/01105
  • Ages 21-90
  • All Genders

Study Summary

This proposed research aims to assess the efficacy and feasibility of the EsoGLOVE in the inpatient rehabilitation setting. 1. Understanding the ability of the EsoGLOVE in providing exercise and assisting stroke patients with completing hand functional tasks, eventually improves patients' motor function and neural recovery.2. To generate evidence on this innovative device and further deploy it in clinical practice. A Health Technology Assessment (HTA) will be generated from this study to evaluate the cost-effectiveness of the intervention.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Aged 21-90 years regardless of lesion size, race

  2. Stroke type: ischemic or haemorrhagic

  3. Medically stable conditions

  4. Fugl-Meyer Assessment (FMA) of upper extremity impairment from 8-47 out of 66, orFMA of upper extremity impairment from 48-56 out of 66 if hand and wrist subscale isnot full score and may still potentially benefit from study programme.

  5. Able to give own consent, comprehend and follow commands

  6. Able to sit upright and maintain sitting balance for at least 45 minutes

  7. Able to stay alert and focus on the tasks at least 45 minutes and more.

  8. Unilateral upper limb impairment

Exclusion

Exclusion Criteria:

  1. Recurrent stroke

  2. Unstable medical conditions (e.g. heart attack, unstable blood pressure, infection,and etc.) or anticipated life expectancy of <1 year.

  3. Significant cognitive and communicative impairment (e.g. severe receptive aphasia,inattention, learning difficulty, and etc).

  4. History of severe depression or active psychiatric disorder.

  5. Severe spasticity (Modified Ashworth scale >3) of the affected distal muscles, jointcontractures or deformity, poor skin conditions (e.g. irritated skin, open wounds),amputation of fingers, and allergic condition (e.g. patients with allergies toadhesive gel).

  6. Poor trunk control or postural hypotension.

Study Design

Total Participants: 61
Treatment Group(s): 3
Primary Treatment: EsoGLOVE with Trigno Biofeedback (EMG sensors)
Phase:
Study Start date:
July 11, 2023
Estimated Completion Date:
August 31, 2025

Study Description

This project proposes a study of 130 subjects in inpatient settings who have sustained their first-ever stroke prior to clinical trial enrolment. Participants are randomly assigned to 2 groups (EsoGLOVE group and GRASP group). The randomization method: A block randomization with a randomly varying block size. The study will last 12 weeks (3 weeks of intervention during hospitalization + 12th-week outpatient follow-up post-discharge). The subjects will use the study device about 15 times and be followed up for 3 weeks during hospitalization.

The subjects will need to visit the doctor's office 1 time (outpatient follow-up post-discharge) in the course of the study.During the hospitalization, the stroke patients (subjects) will receive intensive stroke rehabilitation as per normal, which will be daily physiotherapy and occupational therapy as a part of standard care as per stroke rehabilitation. On top of the standard care (daily Inpatient OT Rehabilitation), the EsoGLOVE subjects will receive EsoGLOVE training on therapy day for 3 weeks (week 1 to week 3, sessions will be done every Monday to Friday), a minimum of 30 minutes per day. While the GRASP group subjects will receive the Graded Repetitive Arm Supplementary Program (GRASP) on therapy day (Monday to Friday) for 3 weeks, a minimum of 30 minutes per day.In the case of early discharge or withdrawal for any reason before the 3-week intervention is completed, the subjects will no longer participate in this study and no study-related activities will be performed on the subjects. The subjects' right to receive standard care will remain the same as per hospital guidelines and will not be affected. This is applicable to both groups. With minimal compliance rate (10 sessions) for continuing the study, regardless of the subjects' discharge before 3 weeks, otherwise (less than or equal to 9 sessions) subjects will be withdrawn at the day of discharge or withdrawal. The 12th-week outpatient follow-up post-discharge at the clinic will coincide with the subject's standard care follow-up visit.The Health Technology Assessment (HTA) is conducted by the study team using explicit analytical frameworks, clinical outcomes, epidemiological data amp; statistics, health economic information, and study methodology. The assessment includes building evidence on the qualities and costs of health interventions (cost-effectiveness), identifying the direct amp; indirect medical costs in the current healthcare system, capturing the clinical outcomes of interventions, synthesizing health research findings of the effectiveness of different health interventions, evaluating the economic implications and analyzing the cost-effectiveness of the intervention.It is unlikely this study might unintentionally come to know of new information (Incidental Finding) about the health condition from the assessment (Fugl-Meyer Assessment - Upper Extremity) of the study.

Connect with a study center

  • Alexandra Hospital

    Singapore,
    Singapore

    Site Not Available

  • Jurong Community Hospital

    Singapore,
    Singapore

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.